Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1881 to 1890 of 2586 total matches.

IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018  (Issue 1561)
-Induced Nausea and Vomiting Drug Formulations Usual Adult Dosage1 Cost2 IV Formulations Aprepitant ...
The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Aprepitant is also available in oral capsule and suspension formulations (Emend, and generics), and fosaprepitant, a prodrug of aprepitant, is available in an IV formulation (Emend for injection).
Med Lett Drugs Ther. 2018 Dec 3;60(1561):e200-1 |  Show IntroductionHide Introduction

An EUA for Sotrovimab for Treatment of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
with the drug.4 An EUA for Sotrovimab for Treatment of COVID-19 CoV-2. Its exact mechanism of action ...
The investigational monoclonal antibody sotrovimab (VIR-7831; GSK/Vir Biotechnology) has been granted an FDA Emergency Use Authorization (EUA) for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death.1 Two other monoclonal antibody regimens are authorized for the same indication: casirivimab (REGN10933) and imdevimab (REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016) administered together. The FDA revoked its EUA...
Med Lett Drugs Ther. 2021 Jun 28;63(1627):97-8 |  Show IntroductionHide Introduction

Statins for High-Risk Patients without Heart Disease or High Cholesterol

   
The Medical Letter on Drugs and Therapeutics • Jan 02, 2006  (Issue 1225)
Letter ® On Drugs and Therapeutics IN THIS ISSUE Statins for High-Risk Patients without Heart ...
The FDA recently approved the use of atorvastatin (Lipitor) to reduce the risk of heart attack and stroke in patients without heart disease who have type 2 diabetes plus other risk factors, with or without hypercholesterolemia. The agency also approved the drug's use to reduce the risk of stroke in high-risk nondiabetic patients without heart disease, whether or not they have hypercholesterolemia. Similar indications were previously approved for simvastatin (Zocor).
Med Lett Drugs Ther. 2006 Jan 2;48(1225):1-2 |  Show IntroductionHide Introduction

Inhaled Insulin (Exubera)

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2006  (Issue 1239)
Letter ® On Drugs and Therapeutics Inhaled Insulin (Exubera) Volume 48 (Issue 1239) July 17, 2006 ...
An inhaled, dry-powder formulation of rapid-acting human insulin (Exubera - Pfizer) has been approved by the FDA for treatment of adults with type 1 or type 2 diabetes.
Med Lett Drugs Ther. 2006 Jul 17;48(1239):57-8 |  Show IntroductionHide Introduction

Continuous Glucose Monitoring

   
The Medical Letter on Drugs and Therapeutics • Feb 12, 2007  (Issue 1254)
Letter ® On Drugs and Therapeutics Continuous Glucose Monitoring Volume 49 (Issue 1254) February ...
A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices, more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Med Lett Drugs Ther. 2007 Feb 12;49(1254):13-5 |  Show IntroductionHide Introduction

Alpha1-Proteinase Inhibitor for Alpha1-Antitrypsin Deficiency

   
The Medical Letter on Drugs and Therapeutics • Mar 11, 1988  (Issue 761)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Human alpha1-proteinase inhibitor (Prolastin Cutter), possibly better known as alpha1-antitypsin (ATT), is now available in the USA for replacement therapy in patients with emphysema who have a congential deficiency of the protein.
Med Lett Drugs Ther. 1988 Mar 11;30(761):29-30 |  Show IntroductionHide Introduction

Is Indapamide (Lozol) Safer Than A Thiazide?

   
The Medical Letter on Drugs and Therapeutics • Nov 17, 1989  (Issue 805)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Recent advertisements for indapamide (Lozol - Rorer), an oral antihypertensive/diuretic (Medical Letter, 26:17, 1984), claim that the drug, unlike thiazide diuretics, does not significantly increase serum cholesterol and has a minimal impact on potassium. Indapamide has no thiazide ring but, like chlorthalidone (Hygroton; and others) and hydrochlorothiazide (HydroDiuril; and others), it does have a sulfamoyl benzamide moiety, which is probably responsible for its natriuretic and diuretic effects. Unlike the thiazides, it also has a methylindoline moiety, which apparently decreases...
Med Lett Drugs Ther. 1989 Nov 17;31(805):103 |  Show IntroductionHide Introduction

Surfactant for Premature Infants With Respiratory Distress

   
The Medical Letter on Drugs and Therapeutics • Jan 12, 1990  (Issue 809)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The US Food and Drug Administration recently approved ''Treatment IND';'; (investigational new drug) protocols for Exosurf (Burroughs Wellcome) and Survanta (Ross), two preparations of surfactant used for prevention and treatment of the respiratory distress syndrome (RDS) in premature newborn infants. Consequently, these drugs will be available to virtually every level-ΙΙΙ neonatal intensive-care unit in the USA.
Med Lett Drugs Ther. 1990 Jan 12;32(809):2-3 |  Show IntroductionHide Introduction

Pegademase

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 1990  (Issue 827)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Pegademase (Adagen - Enzon), bovine adenosine deaminase (ADA) conjugated with polyethylene glycol (PEG), was recently approved by the US Food and Drug Administration as an 'orphan drug' for treatment of severe combined immunodeficiency disease (SCID). SCID due to inherited deficiency of ADA occurs in less than one per million births; until recently, without extraordinary isolation measures, it was usually fatal before the age of two.
Med Lett Drugs Ther. 1990 Sep 21;32(827):87-8 |  Show IntroductionHide Introduction

Ketoconazole Shampoo For Dandruff

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 1994  (Issue 927)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Ketoconazole (Nizoral - Janssen), an imidazole antifungal drug widely used in a tablet formulation for treatment of systemic fungal infections (Medical Letter 36:16, 1994) and as a topical preparation for fungal skin infections, is also available as a shampoo for treatment of seborrheic dandruff. The shampoo is sold only by prescription.
Med Lett Drugs Ther. 1994 Jul 22;36(927):68 |  Show IntroductionHide Introduction